Medscape Today - Novel, Effective Antidepressant Still Not Ready for Prime Time - Nancy A. Melville

New York, NY
 – April 12, 2013  –– 

In the largest clinical trial to test the efficacy of ketamine for the treatment of depression, a single dose of the glutamate N-methyl-D-aspartate receptor antagonist was shown to be significantly more effective than midazolam in reducing treatment-resistant depression over 24 hours. "The idea was that if ketamine resulted in superior antidepressant outcomes compared to midazolam, we could be more confident that ketamine did in fact possess specific antidepressant effects beyond what would be seen with a different anesthetic agent devoid of intrinsic antidepressant properties," said lead author James W. Murrough, MD, an assistant professor of psychiatry and neuroscience and associate director of the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai
-Dr. James Murrough, Assistant Professor, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai
Learn more